CoreCap Advisors LLC Trims Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

CoreCap Advisors LLC trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 727 shares of the medical research company’s stock after selling 30 shares during the quarter. CoreCap Advisors LLC’s holdings in Thermo Fisher Scientific were worth $378,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in TMO. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Thermo Fisher Scientific by 0.7% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 126,603 shares of the medical research company’s stock valued at $65,863,000 after buying an additional 887 shares during the period. Czech National Bank boosted its holdings in shares of Thermo Fisher Scientific by 6.6% during the fourth quarter. Czech National Bank now owns 82,934 shares of the medical research company’s stock worth $43,145,000 after purchasing an additional 5,118 shares during the last quarter. Aprio Wealth Management LLC grew its position in shares of Thermo Fisher Scientific by 17.9% in the fourth quarter. Aprio Wealth Management LLC now owns 1,022 shares of the medical research company’s stock valued at $532,000 after purchasing an additional 155 shares during the period. Fiduciary Alliance LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $811,000. Finally, Capital Investment Advisors LLC boosted its stake in Thermo Fisher Scientific by 15.4% in the 4th quarter. Capital Investment Advisors LLC now owns 1,335 shares of the medical research company’s stock worth $695,000 after buying an additional 178 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $402.93 on Friday. The firm has a 50-day moving average of $464.67 and a two-hundred day moving average of $514.85. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. The stock has a market cap of $152.10 billion, a P/E ratio of 24.38, a PEG ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 1-year low of $401.75 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same quarter last year, the firm earned $5.11 EPS. Thermo Fisher Scientific’s quarterly revenue was up .2% on a year-over-year basis. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.43%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.09%.

Insider Transactions at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 14,075 shares of company stock valued at $7,305,942. Insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TMO. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Wednesday, April 23rd. StockNews.com lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Friday, April 25th. Argus cut their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a research report on Tuesday, April 29th. Citigroup lowered their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Finally, Morgan Stanley raised their price objective on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Five investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $607.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.